Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics (Nasdaq: ALGS) announced that its Compensation Committee granted non-qualified stock options to purchase an aggregate of 14,100 shares as inducement awards to newly hired employees on Dec 9, 2025.
Rhea-AI Summary
Aligos Therapeutics (Nasdaq: ALGS) announced that its Compensation Committee granted non-qualified stock options to purchase an aggregate of 14,100 shares as inducement awards to newly hired employees on Dec 9, 2025. The awards were granted under the company’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price equal to the closing price of Aligos common stock on the grant date and vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly, subject to continued employment.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ALGS
On Dec 12, the day this news came out, ALGS closed 15.51% above the previous close.
Data tracked by StockTitan Argus for the Dec 12 session.
Key Figures
- Inducement options
- 14,100 shares
- Non-qualified stock options granted to new hires on Dec 9, 2025
- Vesting period
- 4 years
- Inducement options vesting schedule
- Initial cliff vesting
- 25%
- Vests on first anniversary of Grant Date
Historical Context
-
Equity inducement options granted to new hires under 2024 plan.
-
Positive HBV suppression data for ALG-000184 at The Liver Meeting.
-
Q3 loss, funding runway into Q3 2026, ongoing trial funding needs.
-
Planned investor conference presentations and webcast availability.
-
Announcement of upcoming Q3 2025 financial results release date.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
non-qualified stock options financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 14,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on December 9, 2025 (the “Grant Date”), in connection with the commencement of employment.
The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.
The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.